BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 21775533)

  • 1. Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy.
    Tan XL; Moyer AM; Fridley BL; Schaid DJ; Niu N; Batzler AJ; Jenkins GD; Abo RP; Li L; Cunningham JM; Sun Z; Yang P; Wang L
    Clin Cancer Res; 2011 Sep; 17(17):5801-11. PubMed ID: 21775533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study.
    Niu N; Schaid DJ; Abo RP; Kalari K; Fridley BL; Feng Q; Jenkins G; Batzler A; Brisbin AG; Cunningham JM; Li L; Sun Z; Yang P; Wang L
    BMC Cancer; 2012 Sep; 12():422. PubMed ID: 23006423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy.
    Moyer AM; Sun Z; Batzler AJ; Li L; Schaid DJ; Yang P; Weinshilboum RM
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):811-21. PubMed ID: 20200426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Genetic variation in DNA polymerase kappa gene is associated with the prognosis after platinum-based chemotherapy in small cell lung cancer patients].
    Chen JN; Feng T; Yang J; Li HM; Yuan P; Ma F; Yin LL; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):112-117. PubMed ID: 30862140
    [No Abstract]   [Full Text] [Related]  

  • 6. [Genetic variation in DNA repair gene RAD52 is associated with the response to platinum-based chemotherapy in SCLC patients].
    Li HM; Yuan P; Yu DK; Ma F; Tan WW; Feng T; Yang J; Huang Y; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2016 Jul; 38(7):504-9. PubMed ID: 27531263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.
    Lee SY; Kang HG; Yoo SS; Kang YR; Choi YY; Lee WK; Choi JE; Jeon HS; Shin KM; Oh IJ; Kim KS; Lee J; Cha SI; Kim CH; Kim YC; Park JY
    Lung Cancer; 2013 Nov; 82(2):330-9. PubMed ID: 23973201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].
    Feng T; Li HM; Yuan P; Yu DK; Ma F; Tan WW; Du ZL; Yang J; Huang Y; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):115-120. PubMed ID: 28219206
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients.
    Takenaka T; Yano T; Kiyohara C; Miura N; Kouso H; Ohba T; Kometani T; Shoji F; Yoshino I; Maehara Y
    Lung Cancer; 2010 Jan; 67(1):101-7. PubMed ID: 19361884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients.
    Xu X; Ren H; Zhou B; Zhao Y; Yuan R; Ma R; Zhou H; Liu Z
    Lung Cancer; 2012 Aug; 77(2):438-42. PubMed ID: 22516052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients.
    Müller PJ; Dally H; Klappenecker CN; Edler L; Jäger B; Gerst M; Spiegelhalder B; Tuengerthal S; Fischer JR; Drings P; Bartsch H; Risch A
    Int J Cancer; 2009 Apr; 124(7):1669-74. PubMed ID: 19107936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Chen X; Sun H; Ren S; Kim Curran V; Zhang L; Zhou S; Zhang J; Zhou C
    Clin Transl Oncol; 2012 Mar; 14(3):207-13. PubMed ID: 22374424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of GWAS-identified lung cancer susceptibility loci with survival length in patients with small-cell lung cancer treated with platinum-based chemotherapy.
    Li D; Wei L; Xu B; Yu D; Chang J; Yuan P; Du Z; Tan W; Shen H; Wu T; Wu C; Lin D
    PLoS One; 2014; 9(11):e113574. PubMed ID: 25415319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy.
    Han JY; Lee YS; Shin ES; Hwang JA; Nam S; Hong SH; Ghang HY; Kim JY; Yoon SJ; Lee JS
    Pharmacogenomics J; 2014 Feb; 14(1):20-7. PubMed ID: 23478653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment.
    Qian J; Gu S; Wu Q; Zhao X; Wu W; Gao Z; Zhang W; Tan X; Wang H; Wang J; Fan W; Chen H; Han B; Lu D; Wei Q; Jin L
    Chest; 2012 Sep; 142(3):680-689. PubMed ID: 22441531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
    Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese.
    Xu JL; Hu LM; Huang MD; Zhao W; Yin YM; Hu ZB; Ma HX; Shen HB; Shu YQ
    Asian Pac J Cancer Prev; 2012; 13(3):851-6. PubMed ID: 22631660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.
    Hong MJ; Lee SY; Choi JE; Jin CC; Kang HJ; Baek SA; Lee SY; Shin KM; Jeong JY; Lee WK; Yoo SS; Lee J; Cha SI; Kim CH; Son JW; Park JY
    Oncotarget; 2016 Mar; 7(13):15948-58. PubMed ID: 26893365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host.
    Gallagher DJ; Vijai J; Hamilton RJ; Ostrovnaya I; Iyer G; Garcia-Grossman IR; Kim PH; Przybylo JA; Alanee S; Riches JC; Regazzi AM; Milowsky MI; Offit K; Bajorin DF
    Ann Oncol; 2013 Sep; 24(9):2414-21. PubMed ID: 23897706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.